Cargando…

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2

A gradual decay in humoral and cellular immune responses over time upon SAR1S-CoV-2 vaccination may cause a lack of protective immunity. We conducted a longitudinal analysis of antibodies, T cells, and monocytes in 25 participants vaccinated with mRNA or ChAdOx1-S up to 12 weeks after the 3(rd) (boo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Özbay Kurt, Feyza Gül, Lepper, Alisa, Gerhards, Catharina, Roemer, Mathis, Lasser, Samantha, Arkhypov, Ihor, Bitsch, Rebekka, Bugert, Peter, Altevogt, Peter, Gouttefangeas, Cécile, Neumaier, Michael, Utikal, Jochen, Umansky, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597683/ https://www.ncbi.nlm.nih.gov/pubmed/36311732 http://dx.doi.org/10.3389/fimmu.2022.1012526

Ejemplares similares

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
por: Lepper, Alisa, et al.
Publicado: (2023)

HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
por: Arkhypov, Ihor, et al.
Publicado: (2022)

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
por: Ozbay Kurt, Feyza Gul, et al.
Publicado: (2023)

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice
por: Bitsch, Rebekka, et al.
Publicado: (2022)

Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
por: Arkhypov, Ihor, et al.
Publicado: (2020)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression
por: Groth, Christopher, et al.
Publicado: (2021)

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
por: Hüser, Laura, et al.
Publicado: (2020)

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
por: Groth, Christopher, et al.
Publicado: (2018)

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
por: Fleming, Viktor, et al.
Publicado: (2018)

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
por: Weber, Rebekka, et al.
Publicado: (2018)

IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
por: Weber, Rebekka, et al.
Publicado: (2020)

Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome
por: Gerhards, Catharina, et al.
Publicado: (2023)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Waning of SARS-CoV-2 booster viral-load reduction effectiveness
por: Levine-Tiefenbrun, Matan, et al.
Publicado: (2022)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination
por: Sasanami, Misaki, et al.
Publicado: (2023)

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies
por: Hüser, Laura, et al.
Publicado: (2019)

Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required
por: Balkan, İlker İnanc, et al.
Publicado: (2022)

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer
por: Shapiro, Lauren C., et al.
Publicado: (2022)

The Waning of the Plague
Publicado: (1897)

SAT-101 The Booster Effect of Aromatase Inhibitor to Overcome Waning Effect of Recombinant Human Growth Hormone
por: Kim, Dae Hyun, et al.
Publicado: (2020)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

SARS‐CoV‐2 booster effect and waning immunity in hemodialysis patients: A cohort study
por: Goggins, Eibhlin, et al.
Publicado: (2023)

The Omicron wave and the waning of COVID-19 vaccine effectiveness. Influence of vaccine booster and age on confirmed infection incidence
por: Corral-Gudino, Luis, et al.
Publicado: (2022)

The waning war on cancer.
Publicado: (1995)

A Waning Superstition
Publicado: (1902)

Mental Disease on the Wane
por: Banschikov, Vasili, et al.
Publicado: (1965)

Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
por: Kittel, Maximilian, et al.
Publicado: (2021)

COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
por: Menni, Cristina, et al.
Publicado: (2022)

Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22
por: Bosetti, Paolo, et al.
Publicado: (2022)

Is the Bacteriological Theory of Disease Waning?
Publicado: (1896)

Is the Influence of the Medical Profession on the Wane?
Publicado: (1890)

Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries
por: Whittaker, Elizabeth, et al.
Publicado: (2018)

Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era
por: Barnard, Rosanna C., et al.
Publicado: (2022)

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa
por: Vesin, Benjamin, et al.
Publicado: (2022)

Recommendation for broad use of Covid-19 mRNA vaccine boosters due to waning vaccine effectiveness is taking the easy way out
por: Schildgen, Verena, et al.
Publicado: (2023)

Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
por: Gerhards, Catharina, et al.
Publicado: (2023)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
por: Tobudic, Selma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m98kpih7eshqngd2v1990l1j7m